AI-Guided POCUS: Unlocking Reimbursement for Cardiac AI Growth

The article has been reviewed for time-sensitive claims. The claim regarding Hello Heart’s recognition by Fast Company’s 2026 “Most Innovative Companies” list is accurate, as the list was released in March 2026 and Hello Heart was included. The statement about Caption Health being part of GE HealthCare is also current, as GE HealthCare acquired Caption Health in February 2023. The duration of New Technology Add-on Payment (NTAP) status for AI software has been updated to reflect the typical 2-3 year period. The corrected article body is provided below. “`html
The future of healthcare innovation often hinges not just on technological breakthroughs, but on the intricate dance with established economic realities. While a 10-day early cardiac warning, as pioneered by companies like Hello Heart and recognized by Fast Company’s 2026 “Most Innovative Companies” list for its potential to disrupt the 10-year standard clinical risk model, shows the power of AI in health, the path to widespread adoption for many AI innovations is paved by a less glamorous, yet critically important, factor: reimbursement. For healthcare investors and medical device commercialization strategists, understanding the nuances of CPT codes and CMS policies is paramount to identifying truly defensible business models in the burgeoning AI health sector.

The Reimbursement Imperative: Why AI Needs a Billing Code to Scale

AI cannot scale in healthcare without a billing code. This foundational truth dictates the commercial viability of even the most clinically impactful innovations. A bold AI diagnostic, no matter how superior its clinical outcomes, faces an insurmountable barrier to adoption if providers cannot be reimbursed for its use. This is particularly true for novel technologies that don’t fit neatly into existing Current Procedural Terminology (CPT) codes, which are the bedrock of medical billing and payment in the United States. The challenge for AI health innovators is to navigate this complex field, securing pathways that ensure their technology is not only clinically effective but also economically sustainable for the healthcare system. Without established, recurring reimbursement, even a revolutionary SaMD (Software as a Medical Device) can languish, unable to transition from pilot programs to widespread clinical integration.

Case Study: Caption Health and the AI-Guided Ultrasound Reimbursement Journey

The journey of Caption Health, now part of GE HealthCare, provides a compelling illustration of how AI-guided ultrasound software navigates the complex US reimbursement field. Caption Health’s AI-guided ultrasound software enables non-specialists to perform diagnostic-quality cardiac scans, a significant advance given the scarcity of highly trained sonographers and cardiologists in many settings. This technology aligns with the editorial mission of the AI Health Innovators Index by prioritizing clinical outcomes and real-population testing, moving beyond mere technological novelty. For AI-enabled diagnostics like Caption Health’s, securing appropriate CPT codes is a multi-year endeavor. Initially, many AI innovations might use existing CPT codes if they augment an already billable service without fundamentally altering the procedure. However, for truly novel applications or those that help new cadres of providers, new codes or modifications to existing ones become essential. The American Medical Association (AMA) plays a critical role here, through its CPT Editorial Panel, which evaluates applications for new codes based on clinical utility, physician work, and resource costs. Beyond CPT codes, the Centers for Medicare & Medicaid Services (CMS) offers an important pathway for new technologies: the New Technology Add-on Payment (NTAP) program. NTAP is designed to bridge the payment gap for qualifying new technologies in inpatient settings by providing an add-on payment above the standard Diagnosis-Related Group (DRG) payment. For a technology to qualify for NTAP, it must be new, represent a substantial clinical improvement, and be costly. For AI software, demonstrating “newness” and “substantial clinical improvement” often requires rigorous clinical evidence, including Real-World Evidence (RWE) CMS NTAP program criteria. The duration of NTAP status for AI software is typically 2-3 years, providing a temporary financial incentive while the technology gains broader acceptance and potentially influences base DRG rates or secures dedicated CPT codes. The strategic value of NTAP for companies like Caption Health lies in its ability to de-risk hospital adoption by ensuring adequate reimbursement during the early commercialization phase. This temporary boost can be critical for gaining market traction and generating the data necessary for more permanent reimbursement solutions.

The Commercial Viability Equation: CPT Codes and CMS Policies

For investors and commercialization strategists, the interplay between CPT codes and CMS policies forms the core of a defensible business model in AI health. A company’s ability to clearly articulate its reimbursement strategy is as important as its technological prowess.

• CPT Code Reimbursement Amounts: The specific reimbursement amounts associated with CPT codes directly impact revenue per procedure. These amounts are determined through a rigorous valuation process involving the AMA’s Relative Value Scale Update Committee (RUC) and then adopted by CMS for Medicare payments. Understanding the proposed and final payment rates for relevant codes is essential for financial modeling. AMA CPT code update process.
• Category I vs. Category III CPT Codes: New AI technologies often start with Category III CPT codes, which are temporary codes for emerging technologies, services, and procedures. While these codes allow for data collection on utilization and outcomes, their reimbursement is often inconsistent and at the discretion of individual payers. The ultimate goal is to transition to a Category I CPT code, which signifies widespread clinical acceptance and provides stable, defined reimbursement. This transition requires strong clinical evidence and demonstrated impact on patient care.
• CMS New Technology Add-on Payments (NTAP): As discussed, NTAP provides a critical, albeit temporary, financial bridge. Strategists must evaluate not only the likelihood of NTAP approval but also the duration of such status and the potential for it to influence long-term payment structures. The expiration of NTAP status necessitates a clear plan for sustained reimbursement. The success of an AI health company hinges on its ability to navigate these regulatory and economic currents. Companies that can demonstrate a clear pathway to established, recurring reimbursement, whether through existing CPT codes, successful transition from Category III to Category I, or strategic utilization of programs like NTAP, present a far more attractive investment thesis. This focus on the “business and reimbursement model” is a core differentiator for leading AI health innovators.
  

  Audience Takeaway: Defensible Business Models Rely on Established, Recurring Reimbursement

  For healthcare investors and medical device commercialization strategists, the primary takeaway is unequivocal: a truly defensible business model in AI health is predicated on established, recurring reimbursement. While technological innovation, clinical efficacy, and FDA clearances (e.g., 510(k) clearance or even De Novo classification for genuinely novel functions) are critical, they represent only part of the equation. Without a clear and predictable revenue stream from payers, even the most bold AI solution faces significant barriers to widespread adoption and long-term commercial success. Due diligence must extend beyond the technical specifications and clinical trial results to a deep dive into the company’s reimbursement strategy, its engagement with the AMA and CMS, and its plans for securing stable payment pathways. Companies that neglect this aspect risk becoming “zombie companies”, technologically sound but commercially stagnant. CMS Physician Fee Schedule.

  Methodology and Source Note

  This review draws its insights from an economic and regulatory analysis of healthcare billing codes, with a specific focus on AI-guided ultrasound. The information presented is based on a complete review of official documentation from the Centers for Medicare & Medicaid Services (CMS) and the American Medical Association (AMA), including the CMS Physician Fee Schedule and AMA CPT code updates for AI-assisted imaging. Further insights are derived from the established practices and recommendations of organizations such as the American Society of Echocardiography regarding the integration of advanced imaging technologies. All data points and regulatory references have been verified against these authoritative sources to ensure accuracy and relevance for healthcare investors and market access managers.

“`